Related Experiment Video
Updated: Jun 21, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Development of commercially viable enantioselective processes for HIV-1 NNRTIs
1DuPont Pharmaceuticals, Chemical Process Research and Development, Chambers Works, PRF-112, Deepwater, NJ 08023, USA. rodney.l.parsons@dupontpharma.com
Abstract:
A review of the process research and development of the quinazolinone-based HIV-1 drug candidates DPC-961 and DPC- 963 is presented. This article details the chronological evolution of the synthetic processes from the original racemic syntheses to routes that enabled the production of kilogram quantities of drug substances and the development of commercially viable processes. This review describes the process development challenges encountered during an accelerated development program.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Retrovirus Life Cycles

